Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

559388 SB 202190 - CAS 152121-30-7 - Calbiochem

SB 202190, CAS 152121-30-7, is a potent, reversible, competitive inhibitor of p38. Inhibits p38 phosphorylation of myelin basic protein. Blocks the activity of p38β (Ki = 16 nM; IC₅₀ = 350 nM).

SB 202190 - CAS 152121-30-7 - Calbiochem: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole, FHPI, p38 MAP Kinase Inhibitor II

Primary Target: p38β
559388
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
152121-30-7C₂₀H₁₄FN₃O

Products

Número de referenciaEmbalaje Cant./Env.
559388-1MG Ampolla de plást. 1 mg
Description
OverviewA potent, reversible, competitive, and cell-permeable inhibitor of p38 MAP kinase. Inhibits p38 phosphorylation of myelin basic protein (MBP) with no effect on the activity of the ERK or JNK MAP kinase subgroups. Also inhibits the kinase activity of p38β (Ki = 16 nM; IC50 = 350 nM) and p38 phosphorylation of activating transcription factor 2 (ATF-2; IC50 = 280 nM). Blocks LPS-induced TNF-α and interleukin biosynthesis. Reported to induce LDL receptor expression in Hep52 cells. A 1 mg/ml solution of SB 202190 (Cat. No. 559397) in anhydrous DMSO is also available.
Catalogue Number559388
Brand Family Calbiochem®
Synonyms4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole, FHPI, p38 MAP Kinase Inhibitor II
References
ReferencesDavies, S.P., et al. 2000. Biochem. J. 351, 95.
Ajizian, S.J., et al. 1999. J. Infect. Dis. 179, 939.
Singh, R.P., et al. 1999. J. Biol. Chem. 274, 19593.
Wang, S.W., et al. 1999. Inflamm. Res. 48, 533.
Gallagher, T.F., et al. 1997. Bioorg. Med. Chem. 5, 49.
LoGrasso, P.V., et al. 1997. Biochem. 36, 10422.
Jiang, Y., et al. 1996. J. Biol. Chem. 271, 17920.
Kramer, R.M., et al. 1996. J. Biol. Chem. 271, 27723.
Li, Z., et al. 1996. Biochem. Biophys. Res. Commun. 228, 334.
Lee, J.C., et al. 1994. Nature 372, 739.
Product Information
CAS number152121-30-7
ATP CompetitiveY
FormPale yellow solid
Hill FormulaC₂₀H₁₄FN₃O
Chemical formulaC₂₀H₁₄FN₃O
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary Targetp38β
Primary Target IC<sub>50</sub>350 nM against the kinase activity of p38β; 280 nM against p38 phosphorylation of activating transcription factor 2 (ATF-2)
Primary Target K<sub>i</sub>16 nM
Purity≥98% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
559388-1MG 04055977192476

Documentation

SB 202190 - CAS 152121-30-7 - Calbiochem Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

SB 202190 - CAS 152121-30-7 - Calbiochem Certificados de análisis

CargoNúmero de lote
559388

Referencias bibliográficas

Visión general referencias
Davies, S.P., et al. 2000. Biochem. J. 351, 95.
Ajizian, S.J., et al. 1999. J. Infect. Dis. 179, 939.
Singh, R.P., et al. 1999. J. Biol. Chem. 274, 19593.
Wang, S.W., et al. 1999. Inflamm. Res. 48, 533.
Gallagher, T.F., et al. 1997. Bioorg. Med. Chem. 5, 49.
LoGrasso, P.V., et al. 1997. Biochem. 36, 10422.
Jiang, Y., et al. 1996. J. Biol. Chem. 271, 17920.
Kramer, R.M., et al. 1996. J. Biol. Chem. 271, 27723.
Li, Z., et al. 1996. Biochem. Biophys. Res. Commun. 228, 334.
Lee, J.C., et al. 1994. Nature 372, 739.

Citas

Título
  • Annika Grabbe and Jurgen Wienands. (2006) Human SLP-65 isoforms contribute differently to activation and apoptosis of B lymphocytes. Blood 108, 3761-3768.
  • Patrick Michl, et al. (2005) CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7, 521-532.
  • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
    		•
    Ficha técnica

    Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

    Revision04-January-2010 RFH
    Synonyms4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H-imidazole, FHPI, p38 MAP Kinase Inhibitor II
    DescriptionA potent, reversible, competitive, and cell-permeable inhibitor of p38 MAP kinase. Inhibits p38 phosphorylation of myelin basic protein (MBP) with no effect on the activity of the ERK or JNK MAP kinase subgroups. Also inhibits the kinase activity of p38β (Ki = 16 nM; IC50 = 350 nM) and p38 phosphorylation of activating transcription factor 2 (ATF-2; IC50 = 280 nM). Blocks LPS-induced TNF-α and interleukin biosynthesis. Reported to induce LDL receptor expression in Hep52 cells.
    FormPale yellow solid
    CAS number152121-30-7
    Chemical formulaC₂₀H₁₄FN₃O
    Structure formulaStructure formula
    Purity≥98% by HPLC
    SolubilityDMSO (50 mg/ml)
    Storage Protect from light
    -20°C
    Do Not Freeze Ok to freeze
    Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
    Toxicity Standard Handling
    ReferencesDavies, S.P., et al. 2000. Biochem. J. 351, 95.
    Ajizian, S.J., et al. 1999. J. Infect. Dis. 179, 939.
    Singh, R.P., et al. 1999. J. Biol. Chem. 274, 19593.
    Wang, S.W., et al. 1999. Inflamm. Res. 48, 533.
    Gallagher, T.F., et al. 1997. Bioorg. Med. Chem. 5, 49.
    LoGrasso, P.V., et al. 1997. Biochem. 36, 10422.
    Jiang, Y., et al. 1996. J. Biol. Chem. 271, 17920.
    Kramer, R.M., et al. 1996. J. Biol. Chem. 271, 27723.
    Li, Z., et al. 1996. Biochem. Biophys. Res. Commun. 228, 334.
    Lee, J.C., et al. 1994. Nature 372, 739.
    Citation
  • Annika Grabbe and Jurgen Wienands. (2006) Human SLP-65 isoforms contribute differently to activation and apoptosis of B lymphocytes. Blood 108, 3761-3768.
  • Patrick Michl, et al. (2005) CUTL1 is a target of TGFβ signaling that enhances cancer cell motility and invasiveness. Cancer Cell 7, 521-532.
  • Yung-Luen Yu, et al. (2005) MAP kinase-mediated phosphorylation of GATA-1 promotes Bcl-XL expression and cell survival. Journal of Biological Chemistry 280, 29533-29542.
    		•